Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

ELRIG Announces Drug Discovery 2012 Keynotes and Workshops

Published: Tuesday, August 14, 2012
Last Updated: Tuesday, August 14, 2012
Bookmark and Share
European Laboratory Robotics Interest Group have announced details of the keynote speakers and workshop programme for its 6th Annual Drug Discovery Conference.

ELRIG is also calling for abstract submissions ( for the main poster sessions and for the SLAS Young Scientist Award, the winner of which will be awarded with an expenses paid trip to present and participate in the Student Poster Competition at SLAS2013, 12th-16th January 2013 in Florida.

Keynote presentations will be given by Dr Steve Rees, Vice-President of Screening Sciences and Sample Management at AstraZeneca, and Section President of SLAS (‘Collaborative Models for Lead Discovery’), and Dr Chris Moxham, Associate Vice President at ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company (‘Eli Lilly and Co.'s Open Innovation Drug Discovery Initiative’). The keynote speakers will also close the meeting with a debate on ‘The Evolving Landscape for Drug Discovery’.

A number of vendor workshop sessions will be held during the event, as well as lunchtime ‘Informatics: Making Knowledge from Laboratory Data’ Seminars on both days of the event. The lunchtime Informatics Seminars are: ‘How best to enable externalisation of drug discovery’ and ‘Knowledge at your finger tips’.
Workshop sessions include: ‘Deeper insights – better prediction of drug safety and efficacy’ from GE Healthcare Drug Discovery Suite; and ‘Early drug de-risking with 3D-cell-culture systems’ with InSphero.

Drug Discovery 2012 is to be held on 5th – 6th September 2012 at the Manchester Central Convention Complex, and features over 100 exhibitor booths, an Innovation Zone, Media Area, Careers Zone and Dragons Den. Registration for the event is free and over 1,000 delegates are expected to attend.

To find out more and to register for the conference please visit

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ELRIG Announces Drug Discovery 2014 Programme and Pre-Conference SLAS Short Courses
Now in its 8th year, the conference and exhibition is the largest drug discovery meeting in the UK, and is expected to attract over 1000 delegates.
Monday, August 04, 2014
ELRIG Announces Speaker Programme for Drug Discovery 2012 Conference
The 6th Annual Drug Discovery Conference, in collaboration with SLAS, will be held at Manchester Central Convention Complex on 5th – 6th September 2012.
Monday, April 30, 2012
ELRIG Drug Discovery 2011
The 5th ELRIG Drug Discovery show, held in Manchester on 7 & 8th September 2011, attracted 1,125 delegates and a record number of exhibitors.
Thursday, September 22, 2011
ELRIG – Cell Based Screening
This was a meeting of records and firsts for ELRIG, being the first meeting of 2011 with record numbers of attendees at a 1 Day meeting.
Tuesday, March 22, 2011
ELRIG Drug Discovery 2011
Preparations are well underway for the 5th Annual ELRIG Drug Discovery Conference to be held at Manchester Central on 7th & 8th September 2011.
Thursday, January 27, 2011
ELRIG Drug Discovery 2010 - Free Online Registration – Book you place Now
ELRIG, the European Laboratory Robotics Interest Group, are proud to announce that FREE registration to Drug Discovery 2010 is open online. Drug Discovery 2010 will be held at the Ricoh Arena, Coventry, UK on 1st and 2nd September 2010.
Monday, August 02, 2010
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Long-Sought Protein Sensor for the ‘Sixth Sense’ Discovered
In a study led by scientists from The Scripps Research Institute (TSRI)the sensor protein for propioception has been identified.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos